FDA Expands the Use of Ibrutinib to Include Combination for Certain Patients With CLL/SLL
January 28th 2019The FDA has approved the use of ibrutinib (Imbruvica®, AbbVie) in combination with obinutuzumab (Gazyva®) for adult patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
Read More